Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma

The mutant IDH1 inhibitor ivosidenib improves outcomes for patients with IDH1-mutated cholangiocarcinoma, but resistance inevitably develops. Mechanisms of resistance and strategies to overcome resistance are poorly understood. Here we describe two patients with IDH1 R132C-mutated metastatic cholang...

Descripción completa

Detalles Bibliográficos
Autores principales: Cleary, James M., Rouaisnel, Betty, Daina, Antoine, Raghavan, Srivatsan, Roller, Lauren A., Huffman, Brandon M., Singh, Harshabad, Wen, Patrick Y., Bardeesy, Nabeel, Zoete, Vincent, Wolpin, Brian M., Losman, Julie-Aurore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440204/
https://www.ncbi.nlm.nih.gov/pubmed/36056177
http://dx.doi.org/10.1038/s41698-022-00304-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440204/
https://www.ncbi.nlm.nih.gov/pubmed/36056177
http://dx.doi.org/10.1038/s41698-022-00304-5

Ejemplares similares